Journal of Blood Disorders & Transfusion

Abstract

Autologous Transplant in Lymphoma: Experience in a Limited Resource Mexican Reference Center

Espinosa-Bautista Karla A, Armengol-Alonso Alejandra, Castro-Sánchez Andrea, Pérez-Álvarez Sandra I and León Eucario

Lymphomas are a heterogeneous group of lymphoproliferative disorder. Treatment of these patients includes chemotherapy and bone marrow transplantation depending on the disease’s sub-type and clinical stage. Autologous bone marrow transplantation has been performed in México at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Non Hodgkin Lymphomas (NHL) and Hodgkin Lymphomas (HL) patients with a poor prognosis during the past 11 years, with a modified BEAM conditioning regimen. The estimated 5-year survival was 65% (91% in HL and 78% in NHL) and disease-free survival 51%, values similar to other published series. T-cell lymphomas were analyzed separately, yielding a DFS and OS of 73% and 73%, respectively. These results are higher to that reported by other groups. In summary, patients with high risk lymphoma can be salvaged with HSCT with a modified conditioning regimen that allows minimize cost and time in developing countries.